Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia

Projektinformationen

AML-VACCiN

ID Finanzhilfevereinbarung: 667713

DOI 10.3030/667713

Projekt abgeschlossen

EK-Unterschriftsdatum 9 Dezember 2015

Startdatum 1 Januar 2016

Enddatum 30 September 2020

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 8 278 716,25

EU-Beitrag € 6 001 482,00

Koordiniert durch

STICHTING AMSTERDAM UMC
Netherlands

Leistungen

Other (1)

Document providing the logo and templates for a uniform corporate look

Websites, patent fillings, videos etc. (2)

Press release on the outcome of the interim analysis on effect DCP-001 vaccination on MRD
Press release on the completion of the Phase IIb study

Documents, reports (2)

Cumulative Expenditure report

Cumulative expenditure report required upon activation of Article 205 GA due to the existence of a 24 month reporting period to be submitted by 30 September 2020

Communication and dissemination plan